Establishment of biotech parks
Office and plant space for investors and incubator
India is among the top 12 destinations for biotechnology in the world, with approximately 3% share in the global Biotechnology industry. India is also the leader in the global supply of DPT, BCG and measles vaccines.
The biotechnology industry in India comprises about 600+ core biotechnology companies, approx. 2600+ biotech startups, 41 BIRAC-supported incubators.
India has the second-highest number of US Food & Drug Administration (USFDA)-approved manufacturing plants outside the US. The country is currently home to more than 523 USFDA approved drug manufacturing facilities.
100% FDI is allowed under the automatic route for greenfield pharma.
100% FDI is allowed under the government route for brownfield pharma in upto 74% FDI is under automatic route and beyond 74% is under the government approval route.
FDI up to 100% is allowed under the automatic route for the manufacturing of medical devices.
For further details, please refer FDI Policy
Tax deduction on R&D expenditure
Annual industrial growth
Bio-pharma revenue share
Bio-agri revenue share
World's largest producer of recombinant Hepatitis B vaccine
World's largest producer of BT Cotton
World's second highest number of USFDA approved plants
The sector is divided into five major segments- Bio-pharma, Bio-services, Bio-agri, Bio-industrial, and Bio-informatics. The biopharmaceutical sector accounts for the largest share of the biotech industry with a share of 55% of total revenues, followed by bio-agri with 22% market share (2018). Bio-services accounted for 16% of the Biotech industry as India is becoming a leading destination for clinical trials, contract research, and manufacturing activities, which is further fuelling the growth of the bio-services sector, while the remaining market is catered by bio-industrial (8%).
India is also one of the first countries to have a department dedicated to Biotechnology. The Department of Biotechnology has also set up BIRAC (Biotechnology Industry Research Assistance Council). This not-for-profit an interface agency to strengthen and empower emerging biotechnology enterprises to undertake strategic research and innovation.
Helix investment Holdings Pte Ltd., Singapore invested $ 12 mn in Concord Biotech Ltd
Tano India Pvt., Mauritius invested $ 7.4 mn in Windlas Biotech Ltd.
Office and plant space for investors and incubator
Host of instrumentation facilities and services
India is world’s leading supplier of affordable vaccines
Industry academia collaboration for Bio-pharma development
Attracted $ 2.8 bn investments between 2012-16
The vision is to create biotechnology enterprise equipped wi…
Bio-incubation allows harnessing of the entrepreneurial pote…
The scheme was established to foster the generation of ideas…
To provide guidelines to applicants to enable them to unders…
It focuses on building coherence and connectivity between di…
The guidelines reiterate that the general principles of biom…
In order to achieve the aforementioned objectives, each inst…
Pharmaceutical Park at Chaygaon
Active Pharmaceutical Ingredients Project [Visakhapatnam]
Bulk Drugs Project [Dahej]
Personalised Immunotherapy Based Cancer Research Facility
The Department of Biotechnology as well as the Biotechnology Industry Research Assistance Council has various schemes to support R&D through centres of excellence, industry partnerships and grants. These schemes are as follows:
a) Centres Of Excellence and Innovation in Biotechnology.
b) Research Resources, Service Facilities and Platforms.
c) Societal Development.
d) Biotech Parks and Incubators.
e) Rapid Grant for Young Investigators.
f) Glue Grant.
g) Special Programmes-North-East region.
h) Women Scientist Scheme.
For more details, you can access the following link.
Yes, BIRAC conducts roadshows and Intellectual Property workshops to sensitize the target audiences about the BIRAC support for the entrepreneurs and relevance of intellectual property. It also provides a platform for the aspiring entrepreneurs to gain knowledge about effective grant writing skills from the experts in the domain.
Yes, the Department does offer support to researchers across all the stages of R&D - Ideation/ very early stage (SITARE, E-yuva), ideation to early stage (Biotechnology Ignition Grant Scheme (BIG)), ideation to late stage (Small Business Innovation Research Initiative (SBIRI)), (Biotechnology Industry Partnership Programme (BIPP)), translation (Promoting Academic Research Conversion to Enterprise (PACE)) and for social innovation (Social Innovation programme for Products: Affordable & Relevant to Societal Health) etc. This support is usually through awards, grants for research, provision of enabling platform for different stakeholders to collaborate and innovate. Usually, a researcher submits his/her proposal to Biotechnology Industry Assistance Council (BIRAC) based on which the support is provided.
Yes, BIRAC and Centre of Entrepreneurial Learning (CEL) of Judge Business School, University of Cambridge have initiated a partnership that enables five BIRAC supported applicants to take part in CfEL’s flagship intensive entrepreneurial boot-camp programme called “IGNITE”, which is aimed at providing academics (PhDs, post-docs and scientists) entrepreneurial opportunities to explore their innovative ideas and transform them into a business project. CfEL provides one week intense mentorship and training to the BIRAC supported candidates and for second week encourage them to interact and learn from the Cambridge’s entrepreneurial cluster.
Grand Challenges is a family of initiatives fostering innovation to solve key global health and development. In 2012, the Bill & Melinda Gates Foundation (BMGF) and the Department of Biotechnology (DBT) signed an umbrella Memorandum of Understanding (MOU) to collaborate on mission-directed research and build Grand Challenges India to support health research and innovation which is the GCI. Under the GCI, proposals are called under various relevant topics on innovative solutions to help expand the pipeline of ideas to develop new preventions, therapies and interventions in this sector.